Vaxart, Inc.
VXRT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -0.74 | -0.05 | -0.04 |
| FCF Yield | 3.01% | -15.35% | -10.49% | -4.90% |
| EV / EBITDA | 0.00 | -8.20 | -6.91 | -17.21 |
| Quality | ||||
| ROIC | 0.00% | -27.50% | -22.55% | -14.11% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | -0.32 | 1.06 | 0.62 | 0.61 |
| Growth | ||||
| Revenue 3-Year CAGR | 293.57% | 525.41% | 440.59% | 544.91% |
| Free Cash Flow Growth | 115.64% | -62.83% | -31.67% | -75.51% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.33 | 0.66 | 0.22 |
| Interest Coverage | 0.00 | -21.73 | -14.98 | -12.44 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 106.82 | 93.02 | 69.50 | 70.94 |